What is the standard first-line chemotherapy regimen for metastatic or recurrent endometrial carcinoma not suitable for hormonal therapy?
- A Cisplatin plus bleomycin plus etoposide
- B Carboplatin plus paclitaxel ✓
- C Gemcitabine plus docetaxel
- D Topotecan single agent
Correct answer: B. Carboplatin plus paclitaxel
Explanation
Carboplatin with paclitaxel is the accepted first-line cytotoxic combination for advanced or recurrent endometrial carcinoma, giving overall response rates of roughly 50 to 60 percent with a tolerable toxicity profile. The cisplatin, bleomycin, etoposide combination belongs to germ cell tumour protocols, gemcitabine-docetaxel is used in soft tissue sarcoma and topotecan is a later-line option. In dMMR tumours, checkpoint inhibitors may be combined with or follow this chemotherapy backbone.
Reference: Berek and Novak's Gynecology, 16th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.